Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Ilumya

- PMLiVE

J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

The drug is the first IL-23 inhibitor approved for children from the age of six

- PMLiVE

FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis

The Stelara biosimilar now offers all dosage forms and strengths of its reference product

- PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE

Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis

Plaque psoriasis affects up to 90% of patients with the immune-mediated disease

- PMLiVE

Bristol Myers Squibb’s Sotyktu shows promise in phase 3 psoriatic arthritis trials

The immune-mediated disease affects approximately 30% of people living with psoriasis

- PMLiVE

AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition

The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease

- PMLiVE

Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis

The immune-mediated disease affects more than 125 million people worldwide

- PMLiVE

Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis

At least 100 million people worldwide are affected by the immune-mediated disease

- PMLiVE

World Psoriasis Day: Almirall highlights impact of disease on patient well-being

Almost 77% of patients believe that psoriasis negatively affects their daily life and well-being

Psoriasis-Awareness-Day

Listening and hearing – how patients’ online behaviour can help us to improve wellbeing in psoriasis.

The following article was developed using information gathered through primary and secondary desk research, including a recent Social Listening project conducted by our team at Mednet.

Mednet

- PMLiVE

BMS launches campaign to highlight impact of psoriasis on patient well-being

An estimated 7.5 million people in the US are affected by some form of the condition

- PMLiVE

Almirall launches mini-series to highlight impact of psoriasis on patient well-being

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links